ERAS Erasca, Inc.
$15.22▲ +1.53%
Healthcare
Other
Volume 5.83M
Avg Volume (10D) 5.02M
Key Metrics & Fundamentals
Market Cap
$5.32B
P/E Ratio
–
Div Yield
0.00%
52W Range
2.11 - 24.28
% vs 50 MA
-2.81%
% vs 200 MA
2.21%
RSI-14
52.7
MACD Histogram
+0.1300
Beta (1Y vs SPY)
1.28
Free Cash Flow
-$27.28M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$46.90M
COGS
–
Operating Exp
$47.62M
Operating Income
-$47.62M
EBIT
-$47.62M
Pretax Income
-$44.08M
Net Income
-$44.08M
EPS (Diluted)
-0.14
Price & Volume History
Loading chart…
Recent News
Erasca (ERAS), What Is Driving Attention Around The Stock Today?
Simply Wall St. · Oct 27, 2026 2:15 PM ET
Erasca (ERAS) Stock Looks Above Fair Value After Its 5x Run
Simply Wall St. · Oct 19, 2026 2:08 AM ET
Sector Update: Healthcare Stocks Softer Late Afternoon
MT Newswires · Oct 16, 2026 3:56 PM ET
Sector Update: Healthcare Stocks Mixed Friday Afternoon
MT Newswires · Oct 16, 2026 1:44 PM ET
Sector Update: Healthcare
MT Newswires · Oct 16, 2026 1:18 PM ET
Erasca Chief Operating Officer to Depart; Shares Fall
MT Newswires · Oct 16, 2026 11:32 AM ET
Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015
GlobeNewswire · Sep 22, 2026 8:30 AM ET
Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.
GlobeNewswire · Sep 16, 2026 8:30 AM ET
Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium
GlobeNewswire · Sep 10, 2026 8:00 AM ET
Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
GlobeNewswire · Sep 8, 2026 7:00 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See ERAS's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.